The Effect of Chlorella Supplementation on Patients With Type 2 Diabetes Mellitus
Launched by DR. BEHNOOD ABBASI · Aug 8, 2018
Trial Information
Current as of June 03, 2025
Completed
Keywords
ClinConnect Summary
This study is a double-blind, randomized controlled trial. 84 patients with type 2 diabetes are recruited. After informing the patients about this study and filling the consent letters, they are randomly assigned into intervention group (n=42) or placebo group (n=42) receiving 1500 mg chlorella Vulgaris or placebo daily for 8 weeks. Patients are asked not to change their regular physical activity, diet, medicine and dosage during the study. Anthropometric and blood pressure measurements are collected and 24-hour food intake recall, IPAQ physical activity, Pittsburgh Sleep Quality Assessment...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Tendency to participate
- • Clinical diagnosis of T2DM
- • Having T2DM for at least 1 year
- • Range of HbA1c between 6.5% and 8.5%
- • Triglyceride range lower than 300 mg/dl
- Exclusion Criteria:
- • Insulin dependent patients
- • Smoking and alcohol consumption
- • Patients with cardiovascular disease, liver disease, renal and thyroid diseases
- • Pregnancy, lactation and menopause
- • Intake of multivitamin and mineral supplements
About Dr. Behnood Abbasi
Dr. Behnood Abbasi is a distinguished clinical trial sponsor with a robust background in medical research and a commitment to advancing healthcare through innovative studies. With a focus on enhancing patient outcomes and safety, Dr. Abbasi leads clinical trials that explore cutting-edge therapies and interventions across various medical disciplines. His expertise in trial design, regulatory compliance, and data analysis ensures that studies are conducted with the highest ethical standards and scientific rigor. Dr. Abbasi's dedication to collaboration and transparency fosters strong partnerships with healthcare professionals, regulatory bodies, and patient communities, driving progress in clinical research and translating findings into meaningful clinical applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tehran, , Iran, Islamic Republic Of
Patients applied
Trial Officials
Ali Keshavarz, Ph.D.
Principal Investigator
Islamic Azad University,Science and Research Branch
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials